JSS Stock Overview Develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. More details
Rewards Risk Analysis No risks detected for JSS from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Nxera Pharma Co., Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Nxera Pharma Historical stock prices Current Share Price JP¥6.10 52 Week High JP¥11.80 52 Week Low JP¥5.65 Beta 0.66 1 Month Change -1.61% 3 Month Change -14.08% 1 Year Change -31.07% 3 Year Change -48.74% 5 Year Change -64.12% Change since IPO -24.97%
Recent News & Updates
Nxera Pharma Co., Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025 Jan 03
Nxera Pharma Co., Ltd Enrolls First Insomnia Patient in Its Phase 3 Clinical Trial of Daridorexant in South Korea Dec 05
Third quarter 2024 earnings released: EPS: JP¥13.35 (vs JP¥59.82 loss in 3Q 2023) Nov 03
Nxera Pharma Co., Ltd. Appoints Makoto Sugita as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer of Nxera Pharma Oct 01
Nxera Pharma Co., Ltd. to Report Q3, 2024 Results on Nov 01, 2024 Sep 12
New minor risk - Share price stability Aug 30 See more updates
Nxera Pharma Co., Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025 Jan 03
Nxera Pharma Co., Ltd Enrolls First Insomnia Patient in Its Phase 3 Clinical Trial of Daridorexant in South Korea Dec 05
Third quarter 2024 earnings released: EPS: JP¥13.35 (vs JP¥59.82 loss in 3Q 2023) Nov 03
Nxera Pharma Co., Ltd. Appoints Makoto Sugita as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer of Nxera Pharma Oct 01
Nxera Pharma Co., Ltd. to Report Q3, 2024 Results on Nov 01, 2024 Sep 12
New minor risk - Share price stability Aug 30
Second quarter 2024 earnings released: JP¥15.86 loss per share (vs JP¥8.01 loss in 2Q 2023) Aug 13
Nxera Pharma Co., Ltd. to Report Q2, 2024 Results on Aug 09, 2024 Jun 15
First quarter 2024 earnings released: JP¥36.68 loss per share (vs JP¥17.11 loss in 1Q 2023) May 10
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568 Apr 16
Nxera Pharma Appoints Patrick Branch as Head of Business Development for Japan and APAC Apr 03
Sosei Group Corporation Doses First Subject in a Phase 1 Trial Evaluating its Novel EP4 Receptor Agonist, HTL0033744 (HTL'744) for the Treatment of Inflammatory Bowel Disease Mar 21
Sosei Group Corporation to Report Q1, 2024 Results on May 09, 2024 Mar 08
Now 22% undervalued after recent price drop Feb 16
Full year 2023 earnings released: JP¥87.17 loss per share (vs JP¥4.67 profit in FY 2022) Feb 14
Sosei Group Corporation, Annual General Meeting, Mar 27, 2024 Feb 13
New minor risk - Share price stability Jan 27
Sosei Group Corporation Appoints Toshihiro Maeda as Chief Operating Officer Jan 05
New minor risk - Shareholder dilution Dec 16
Sosei Group Corporation Announces Marketing Approval for PIVLAZ (Clazosentan Sodium) 150 Mg in South Korea Dec 07
Sosei Group Corporation to Report Fiscal Year 2023 Results on Feb 13, 2024 Nov 30
New major risk - Financial position Nov 12
Idorsia Pharmaceuticals Japan Ltd. Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for the Approval of Daridorexant Nov 01
Sosei Group Corporation to Report Q3, 2023 Results on Nov 10, 2023 Aug 27
Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732 Aug 10
Second quarter 2023 earnings released: JP¥8.01 loss per share (vs JP¥17.95 loss in 2Q 2022) Aug 07
Sosei Group Corporation (TSE:4565) entered into an agreement to acquire Idorsia Pharmaceuticals Japan Ltd/Idorsia Pharmaceuticals Korea Co., Ltd from Idorsia Ltd (SWX:IDIA) for JPY 65 billion. Jul 22
Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia Jul 04
New minor risk - Share price stability Jun 27
Sosei Group Corporation to Report Q2, 2023 Results on Aug 04, 2023 Jun 26
First quarter 2023 earnings released: JP¥17.11 loss per share (vs JP¥25.39 loss in 1Q 2022) May 16
Now 22% undervalued May 11
Full year 2022 earnings released: EPS: JP¥4.67 (vs JP¥12.53 in FY 2021) Mar 28
Full year 2022 earnings released: EPS: JP¥4.67 (vs JP¥12.53 in FY 2021) Feb 17
Sosei Group Corporation, Annual General Meeting, Mar 23, 2023 Feb 14
Sosei Group Corporation to Report Fiscal Year 2022 Results on Feb 14, 2023 Dec 06
Third quarter 2022 earnings released: EPS: JP¥3.82 (vs JP¥5.80 in 3Q 2021) Nov 16
Third quarter 2022 earnings released: EPS: JP¥3.82 (vs JP¥5.80 in 3Q 2021) Nov 13
Sosei Group Corporation to Report Q3, 2022 Results on Nov 11, 2022 Sep 10
Second quarter 2022 earnings released: JP¥17.95 loss per share (vs JP¥14.11 loss in 2Q 2021) Aug 12
Sosei Heptares' Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development Under Multi-Program Collaboration with Neurocrine Biosciences Aug 06
Cancer Research UK and Sosei Heptares Signs Agreement to Advance Cancer Immunotherapy Candidate into Clinical Trials Jul 22
Sosei Group Corporation to Report Q2, 2022 Results on Aug 10, 2022 Jun 03
First quarter 2022 earnings released: JP¥25.39 loss per share (vs JP¥14.28 loss in 1Q 2021) May 15
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 11
Sosei Group Corporation, Annual General Meeting, Mar 24, 2022 Feb 01
Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19 Dec 09
Third quarter 2021 earnings released: EPS JP¥5.80 (vs JP¥5.94 in 3Q 2020) Nov 12
Second quarter 2021 earnings released: JP¥14.11 loss per share (vs JP¥17.76 loss in 2Q 2020) Aug 13
High number of new directors Jul 31
Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven Jun 24
Sosei Group Corporation Provides Update of Their Strategic Multi-Target Drug Discovery Collaboration with Pfizer May 19
First quarter 2021 earnings released: JP¥14.28 loss per share (vs JP¥9.68 loss in 1Q 2020) May 14
Full year 2020 earnings released: EPS JP¥18.78 (vs JP¥18.69 in FY 2019) Mar 30
Sosei Group Corporation to Report Q1, 2021 Results on May 12, 2021 Mar 20
Full year 2020 earnings released: EPS JP¥18.78 (vs JP¥18.69 in FY 2019) Feb 14
Revenue misses expectations Feb 14
Sosei Group Corporation, Annual General Meeting, Mar 24, 2021 Feb 12
Sosei Heptares to Explore Structure-Based Drug Discovery (SBDD) Approaches to Ion Channels Through Strategic Technology Collaboration with Metrion Biosciences Feb 01
Sosei Heptares and PharmEnable Enter Technology Collaboration for AI-Driven Drug Discovery Against Challenging GPCR Target Jan 12
New 90-day high: €14.40 Jan 08
Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs Jan 05 Sosei Group Corporation's Brand Sosei Heptares and Captor Therapeutics SA Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design
New 90-day high: €13.50 Dec 23
Sosei Group Corporation to Report Fiscal Year 2020 Results on Feb 12, 2021 Dec 05
Sosei Group Corporation and Biohaven Pharmaceutical Holding Company Ltd. Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio Dec 02
Sosei Group Corporation Announces Progress Update for Its R&D Program Focused on the Design and Development of Novel Drugs Targeting the SARS-CoV-2 Coronavirus and to Treat COVID-19 Nov 21
Third quarter 2020 earnings released: EPS JP¥5.93 Nov 15
New 90-day high: €11.30 Nov 07
Sosei Heptares Announces a Second Novel Drug Candidate from its Multi-Target Drug Discovery Collaboration with Pfizer Starts Clinical Trials Oct 05
Sosei Group Corporation to Report Q3, 2020 Results on Nov 11, 2020 Sep 11
New 90-day low - €10.40 Aug 28
First half earnings released Aug 14
Sosei Group Corporation has completed a Follow-on Equity Offering in the amount of ¥5.265733 billion. Jul 18
Sosei Group Corporation to Report Q2, 2020 Results on Aug 13, 2020 Jul 05 Shareholder Returns JSS DE Pharmaceuticals DE Market 7D 1.7% 1.7% 3.0% 1Y -31.1% -14.4% 12.8%
See full shareholder returns
Return vs Market: JSS underperformed the German Market which returned 12.8% over the past year.
Price Volatility Is JSS's price volatile compared to industry and market? JSS volatility JSS Average Weekly Movement 6.2% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: JSS has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: JSS's weekly volatility (6%) has been stable over the past year.
About the Company Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company’s development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders.
Show more Nxera Pharma Co., Ltd. Fundamentals Summary How do Nxera Pharma's earnings and revenue compare to its market cap? JSS fundamental statistics Market cap €557.95m Earnings (TTM ) -€23.08m Revenue (TTM ) €182.05m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) JSS income statement (TTM ) Revenue JP¥29.28b Cost of Revenue JP¥5.43b Gross Profit JP¥23.85b Other Expenses JP¥27.56b Earnings -JP¥3.71b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
Earnings per share (EPS) -41.28 Gross Margin 81.46% Net Profit Margin -12.68% Debt/Equity Ratio 95.8%
How did JSS perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/20 15:03 End of Day Share Price 2025/01/17 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Nxera Pharma Co., Ltd. is covered by 18 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Koichi Mamegano BofA Global Research Hidemaru Yamaguchi Citigroup Inc null null Credit Suisse
Show 15 more analysts 
